TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Carotid Intima-media Thickness in Japan Statin Treatment Against Recurrent Stroke(J-STARS Echo)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ischemic stroke except for cardiogenic embolism, from 1 month to 3 years after onset~* Hyperlipidemia and total cholesterol level of 180-240mg/dl without the prescription of statin within previous 30 days~* Able to visit outpatient department~* Informed consent on the form.~Exclusion Criteria:~* Ischemic stroke of other determined cause according to the TOAST classification~* Ischemic heart disease and necessary to use statin~* Hemorrhagic disorders~* Platelet count \<=100,000/ul within 3 months prior to study start~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)\>= 100IU/L within 3 months prior to study start~* Serum creatinine \>=2.0mg/dl within 3 months prior to study start~* A scheduled operation~* The presence of malignant disorder~* Patients whom carotid ultrasound cannot examine because of neck tumor or torticollis~* Patients after carotid endarterectomy or radiation therapy to neck~* Patients whose carotid ultrasound cannot be examined because of neck tumor or torticollis~* Patients after carotid endarterectomy or radiation therapy to neck

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pravastatin (Type: ACTIVE_COMPARATOR): Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
- No intervention (Type: NO_INTERVENTION): Patient has no intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia (DSM-IV criteria)~* Postmenopausal patients. Postmenopause is defined as after a period of one year of spontaneous amenorrhea and a serum follicle stimulating hormone (FSH) level \> 20IU/L.~* Stable doses of their current antipsychotic medication for at least a month prior to study initiation.~* Presence of significant negative symptoms (defined as one or more negative symptom score greater than 4 in the PANSS scale) (Kay 1987)~* Patients have to give written informed consent to participate in the study.~Exclusion Criteria:~* Patients with a substance abuse/dependence diagnosis in the previous six months.~* Mental retardation.~* Endocrine abnormalities, acute or chronic liver disease, impaired kidney function.~* History of thromboembolism, breast cancer, abnormal uterine bleeding, history of cerebrovascular accident.~* Patients taking hormone replacement therapy.~* Patients taking mood stabilizer medication that cannot be discontinued.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sugar pill (Type: PLACEBO_COMPARATOR): None
- raloxifene hydrochloride (Type: ACTIVE_COMPARATOR): Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Allopurinol to Prevent Cirrhosis Related Morbidities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ge 18 to 75 years old Both sex Adults with cirrhosis in a stable conditions~Exclusion Criteria:~* Active SBP Renal insufficiency (serum creatinine \> 2.0 mg/dl) Active GIT hemorrhage

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Group1: (Placebo, n=50) who will receive oral placebo tablet once daily FOR 6 MONTHS
- allopurinol (Type: ACTIVE_COMPARATOR): Group 2:(Allopurinol n=50) who will receive oral allopurinol 300 mg daily for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age ≥ 18 yrs and \<70 yrs with histologically or cytologically confirmed~* Malignant disease~* Naive or nonnaive to chemotherapy, with a Karnofsky score of ≥ 60~* Scheduled to receive two courses of moderately emetogenic chemotherapy or cisplatin 60 \~ 80 mg/m2 on study Day 1~* Use of reliable contraceptive measures (for females of childbearing potential) and negative pregnancy test at baseline visit~* Patients with hepatic, renal, or cardiovascular impairment eligible at the investigator's discretion~* Patients experiencing, at maximum, mild nausea after previous chemotherapy eligible at the investigator's discretion~* Predicted life expectancy of ≥ 3 months~* Provision of written informed consent.~Exclusion Criteria:~* Inability to understand or cooperate with study procedures~* Receipt of investigational drugs ≤ 30 days before study entry~* Receipt of other investigational drugs during the course of this study~* Seizure disorder or any condition requiring anticonvulsants, sedatives~* CNS malignancy or metastasis~* Ongoing emesis due to obstruction of digestive tract~* Emesis, retching, or Grade 2 or 3 nausea 24 hrs before chemotherapy~* Moderate or severe nausea and vomiting after any previous chemotherapy~* Scheduled receipt of any chemotherapeutic agent with an emetogenicity level \>3 during study Days 2-5~* Scheduled receipt of radiotherapy of the upper abdomen or cranium on study Days 2-5~* Scheduled to receive any other drug with potential antiemetic efficacy within 24 h of study initiation and throughout day 5~* Contraindications to 5-HT3 receptor antagonists~* Contraindications to chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes~* Currently being treated with the following: Dual or triple oral therapy - on a stable combination and dose for at least 3 months.~* HbA1c between 7.5% and 10.0%.~* BMI \>27.~Exclusion Criteria:~* Receive chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to study.~* Have participated in an interventional medical, surgical, or pharmaceutical study (a study in which a medical or surgical treatment was given) within 30 days prior to entry into the study.~* Treatment with the following medications: \*Insulin as outpatient therapy within last 3 months; \*Meglitinides, or acarbose within the last 3 months; \*Regular use of any drugs that directly affect gastrointestinal motility; \*Any previous (study) therapy with exenatide or glucagon-like peptide-1 (GLP-1) analogue; \*Anti-obesity agent use within the last 3 months.~* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Leptin to Treat Lipodystrophy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~All ethnic groups.~Males and females.~* Age greater than or equal to 6 months.~* Clinically significant lipodystrophy, identified by the study physician during the physical examination as an absence of fat outside the range of normal variation and/or identified as a disfiguring factor by the patient.~Circulating leptin levels less than 12.0 ng/ml in females and less than 8.0 ng/ml in males as measured by Linco assay on a specimen obtained after an overnight fast. In children ages 6 months 5 years, a circulating leptin level of less than 6 ng/mL will be used. Leptin samples will be run through Millipore Laboratories, who use the Linco Assay, which has been the assay previously used to measure leptin levels throughout this study period.~Presence of at least one of the following metabolic abnormalities:~1. Presence of diabetes as defined by the 2007 ADA criteria~   1. Fasting plasma glucose greater than or equal to 126 mg/dL, or~  2. 2 hour plasma glucose greater than or equal to 200 mg/dL following a 75 gram (1.75gm/kg) oral glucose load, or~  3. Diabetic symptoms with a random plasma glucose greater than or equal to 200 mg/dl~2. Fasting insulin greater than 30 micro units/ml.~3. Fasting hypertriglyceridemia greater than 200 mg/dL or postprandially elevated triglycerides greater than 500 mg/dL when fasting is clinically not indicated (e.g. in infants)~   -Persons with impaired decision-making capacity and who may be unable to provide informed consent may participate in this study per the discretion of the Principal Investigator.~   EXCLUSION CRITERIA:~   Pregnant women, women in their reproductive years who do not use an effective method of birth control, and women currently nursing or lactating within 6 weeks of having completed nursing.~   Exclusions for underlying diseases likely to increase side effects or hinder objective data collection:~  * Known infectious liver disease~  * Known HIV infection~  * Current alcohol or substance abuse~  * Psychiatric disorder impeding competence or compliance~  * Active tuberculosis~  * Use of anorexiogenic drugs~  * Other condition(s) which in the opinion of the clinical investigators would impede completion of the study~  * Subjects who have known hypersensitivity to E. Coli derived proteins.~  * Subjects with acquired lipodystrophy and a hematologic abnormality such as neutropenia and/or lymphadenopathy

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metreleptin (Type: EXPERIMENTAL): subcutaneous metreleptin injections in one to two daily doses ranging from 0.06 to 0.24 mg/kg per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV infected subjects that are naive to anti-HIV therapy.~* History of a positive HIV test.~* At least 1000 copies/mL of HIV in their blood as screening.~Exclusion Criteria:~* Active HIV-related diseases.~* Taking other investigational drugs.~* Pregnant or breastfeeding females.~* Not be suitable to participate per investigator opinion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study For Pregabalin In Patients With Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, at least 18 years of age~* Meeting the ACR (America College of Rheumatology) criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites)~* At screening (V1) and randomization (V2), patients must have a score of no less than 40 mm on the Pain Visual Analog Scale (VAS)~* At randomization (V2), at least 4 pain diaries must be completed satisfactorily within the last 7 days and the average pain score must be no less than 4~Exclusion Criteria:~* Patients with no less than 30% decrease on the Pain Visual Analog Scale (VAS) at randomization (V2) as compared to screening (V1)~* Patients with other severe pain due to other conditions (eg, DPN or PHN) that may confound assessment or self-evaluation of the pain associated with fibromyalgia~* Patients with any widespread inflammatory musculoskeletal disorders, widespread rheumatic diseases other than fibromyalgia, active infections, or untreated endocrine disorders~* CLcr less than 60 mL/min (estimated from serum creatinine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pregabalin (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): Matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female;~* Histologically proven stage 0-III invasive carcinoma of the breast that is ER and/or PR positive by immunohistochemical staining, who are receiving a standard dose of aromatase inhibitor (AI) therapy (letrozole 2.5mg once daily or exemestane 25mg once daily or anastrozole 1mg once daily). Women with oligometastatic disease may be included at the discretion of the principal investigator. Surgical resection, chemotherapy, and radiation therapy must have been completed at the time of study enrollment, with the exception of trastuzumab;~* AI therapy has been ongoing for ≥ 2 weeks and treatment is expected to continue;~* AI-associated musculoskeletal symptoms, defined as:~  * Grade 1 or higher musculoskeletal pain that developed or worsened (6 or 7 on CGICS) during AI therapy or~ * Grade 1 or higher sensory neuropathy that developed or worsened (6 or 7 on CGICS) during AI therapy;~* Average pain of ≥4 on the 11-point Likert scale of question #5 of the Brief Pain Inventory;~* ECOG performance status 0-2;~* Willing and able to sign an informed consent document.~Exclusion Criteria:~* Known hypersensitivity to duloxetine or any of the inactive ingredients;~* New musculoskeletal pain that is due specifically to fracture or traumatic injury;~* Treatment with monoamine oxidase inhibitors (MAO-I) within 14 days of enrollment;~* Concurrent treatment with phenothiazines (including thioridazine), propafenone, flecainide, triptans, MAO-Is, SSRIs, SNRIs, or tricyclic antidepressants;~* Currently primary psychiatric diagnosis (schizophrenia, psychosis) or suicidal ideation, history of bipolar disorder, or seizure disorder;~* Chronic liver disease, end stage renal disease, or creatinine clearance \< 30 mL/min as defined by the Cockroft-Gault equation;~* Uncontrolled narrow-angle glaucoma or clinically significant coagulation disorder;~* Pregnant or breast feeding;~* History of alcohol or other substance abuse or dependence within the year prior to enrollment;~* Serious or unstable medical condition that could likely lead to hospitalization during the course of the study or compromise study participation.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Provided written informed consent~* Males agree not to donate sperm and either be abstinent or use adequate contraception. Females to be post-menopausal or surgically sterile~* Non-smoker or ex-smoker \>6 months~* Diagnosed asthma for at least 6 months~* Pre-bronchodilator FEV1 ≥60% and ≤90% of predicted normal value and ≥1.5 L at screening~* Increase in FEV1 of 15% within 30 minutes after a 2.5mg dose of nebulised salbutamol~* Systolic blood pressure 90 to 145 mmHg, diastolic blood pressure 50 to 90 mmHg and heart rate 45 to 80 beats per minute (bpm) after resting for 5 minutes in a supine position (average from two measurements)~* Capable of withdrawing from LABAs, LAMAs and SAMAs before screening and during study and SABAs before screening and for 8 hours before each dose~Exclusion Criteria:~* Asthma exacerbation in the last 3 months~* Any prior life threatening episode of asthma (intensive care admission)~* Any clinically significant disease or disorder or clinically relevant screening result~* QTcF interval \>450 ms or QT interval \>500 ms or other abnormality in ECG~* History of ischemic heart disease or heart failure. History of recurrent or current clinically significant arrhythmia or ECG abnormality as judged by the investigator~* Treatment with systemic glucocorticosteroids within 30 days before screening~* A suspected/manifested infection according to WHO risk classification 2, 3 or 4

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Single dose of nebulised placebo solution
- RPL554 Dose 1 (Type: EXPERIMENTAL): 0.4 mg single dose nebulised RPL554
- RPL554 Dose 2 (Type: EXPERIMENTAL): 1.5 mg single dose nebulised RPL554
- RPL554 Dose 3 (Type: EXPERIMENTAL): 6 mg single dose nebulised RPL554
- RPL554 Dose 4 (Type: EXPERIMENTAL): 24 mg single dose nebulised RPL554
- Salbutamol Dose 1 (Type: ACTIVE_COMPARATOR): 2.5 mg single dose nebulised salbutamol
- Salbutamol Dose 2 (Type: ACTIVE_COMPARATOR): 7.5 mg single dose nebulised salbutamol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects at least 12 years old and in good general health.~* Mild to moderate plaque-type psoriasis~Exclusion Criteria:~* Known allergy or other adverse reaction to calcipotriene or other vitamin D analogs; or to any component of the investigational formulations~* History of hypercalcemia or of vitamin D toxicity.~* Diagnosis of generalized pustular or erythrodermic exfoliative psoriasis.~* Other serious skin disorder or any chronic medical condition that is not well controlled.~* Use of non-biologic systemic anti-psoriatic therapy or biologic therapy within four weeks of enrollment.~* Use of topical therapies that have a known beneficial effect on psoriasis, within 2 weeks of enrollment.~* Systemic medications for other medical conditions that are known to affect psoriasis within the past four weeks of enrollment.~* Use of any investigational therapy within 4 weeks of enrollment.~* Pregnant women, women who are breast feeding, or sexually active women of child bearing potential who are not practicing an acceptable method of birth control.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- U0267 foam (Type: EXPERIMENTAL): U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
- Vehicle foam (Type: PLACEBO_COMPARATOR): Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete